Topical imiquimod in the treatment of large facial keratoacanthomas

Giornale Italiano di Dermatologia e Venereologia

Volumn 147, Issue 5, 2012, Pages 505-506

  Cecchi, R ^a   Bartoli, L ^a   Brunetti, L ^a   Pavesi, M ^a  

^a Hospital of Pistoia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

APOPTOSIS; CELL MATURATION; CREAM; DEMENTIA; FACIAL KERATOACANTHOMA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; INNATE IMMUNITY; KERATOACANTHOMA; LANGERHANS CELL; LETTER; LYMPHOCYTE PROLIFERATION; MACROPHAGE; NATURAL KILLER CELL; SCAR; TREATMENT DURATION; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AGED, 80 AND OVER; AMINOQUINOLINES; FACE; FEMALE; HUMANS; KERATOACANTHOMA; MALE;

EID: 84869401177     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. th Edition. New York: McGraw-Hill; 2008. p. 1049-53.
2. Navi D, Huntley A. Imiquimod 5 percent cream and the treatment of cutaneous malignancy. Dermatol Online J 2004;10:4.
3. Dendorfer M, Oppel T, Wollenberg A, Prinz JC. Topical treatment with imiquimod may induce regression of facial keratoacanthoma. Eur J Dermatol 2003;13:80-2.
4. Calista D, Morri M. Topical imiquimod for the treatment of keratoacanthomas. Eur J Dermatol 2008;18:590-1.
5. Jeon HC, Choi M, Paik SH, Ahn CH, Cho KH. Treatment of keratoacanthoma with 5% imiquimod cream and review of the previous report. Ann Dermatol 2011;23:357-61.